If you have been reading about obesity research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
==== MeSH E05.598.500 – disease models, animal ==== MeSH E05.598.500.249 – arthritis, experimental MeSH E05.598.500.374 – diabetes mellitus, experimental MeSH E05.598.500.468 – liver cirrhosis, experimental MeSH E05.598.500.496 – neoplasms, experimental MeSH E05.598.500.496.500 – leukemia, experimental MeSH E05.598.500.496.750 – liver neoplasms, experimental MeSH E05.598.500.496.843 – mammary neoplasms, experimental MeSH E05.598.500.496.937 – melanoma, experimental MeSH E05.598.500.496.968 – sarcoma, experimental MeSH E05.598.500.500 – nervous system autoimmune disease, experimental MeSH E05.598.500.500.500 – encephalomyelitis, autoimmune, experimental MeSH E05.598.500.500.750 – myasthenia gravis, autoimmune, experimental MeSH E05.598.500.500.875 – neuritis, autoimmune, experimental MeSH E05.598.500.750 – radiation injuries, experimental
==== Ototoxicity ==== Attempts to establish rates of vancomycin-induced ototoxicity are even more difficult due to lack of good data. The consensus is that clearly related cases of vancomycin ototoxicity are rare. The association between vancomycin serum levels and ototoxicity is also uncertain. Cases of ototoxicity have been reported in patients whose vancomycin serum level exceeded 80 μg/mL, but cases have also been reported in patients with therapeutic levels. Thus it remains unknown whether therapeutic drug monitoring of vancomycin for the purpose of maintaining "therapeutic" levels prevents ototoxicity. Still, therapeutic drug monitoring can be used during vancomycin therapy to minimize the risk of ototoxicity associated with excessive drug exposure.
As of this edit, this article uses content from "Anatomy and Physiology", which is licensed in a way that permits reuse under the Creative Commons Attribution-ShareAlike 3.0 Unported License, but not under the GFDL. All relevant terms must be followed.
== Dosage forms == Alprazolam regular release and orally disintegrating tablets are available as 0.25 mg, 0.5 mg, 1 mg, and 2 mg tablets. Extended-release tablets are available as 0.5 mg, 1 mg, 2 mg, and 3 mg tablets. Liquid alprazolam is available in a 1 mg/mL oral concentrate.
Sources: en.wikipedia.org
== In popular culture == In 2016, Singaporean director Boo Junfeng directed and released a film titled Apprentice, starring Firdaus Rahman and Wan Hanafi Su. The film, which narrates the fictional story of newly appointed prison officer and executioner Aiman Yusof, touched on the subject of the death penalty in Singapore and an executioner's perspective of the practice, as well as the experiences and ostracisation of the families when their loved ones were tried and executed. The director also revealed that he had gathered information through interviews of the retired executioners, imams and priests who counselled the death row inmates, and also the families of the executed prisoners while producing the film. The film, which was released in several international film festivals, was met with positive public responses and it attracted both nominations and awards for the director and production team. In Singapore, there were local crime shows like In Cold Blood, Crimewatch, and True Files which re-enact the real-life crimes in Singapore. Among these cases, there were murder and drug trafficking cases which attract the death penalty in the city-state. Often, the re-enactments of these capital cases would also show the final verdicts of the convicts, where it revealed the dates of their sentencing and/or executions. Notably, executed criminals like English serial killer John Martin Scripps, child killer Adrian Lim, notorious wife-killer Anthony Ler and cop-killer Zainal Abidin Abdul Malik featured in these re-enactment shows since the 1980s till the present.
== History == George Gulliver in 1841 drew pictures of platelets using the twin lens (compound) microscope invented in 1830 by Joseph Jackson Lister. This microscope improved resolution sufficiently to make it possible to see platelets for the first time. William Addison in 1842 drew pictures of a platelet-fibrin clot. Lionel Beale in 1864 was the first to publish a drawing showing platelets. Max Schultze in 1865 described what he called "spherules", which he noted were much smaller than red blood cells, occasionally clumped, and were sometimes found in collections of fibrin material. Giulio Bizzozero in 1882 studied the blood of amphibians microscopically in vivo. He named Schultze's spherules (It.) piastrine: little plates. Bizzozero possibly proposed the name Blutplattchen. William Osler observed platelets and, in published lectures in 1886, called them a third corpuscle and a blood plaque; and described them as "a colorless protoplasmic disc". James Wright examined blood smears using the stain named for him, and used the term plates in his 1906 publication, changing to platelets in his 1910 publication.
=== 1986 === January 1, 1986 – Reagan and Gorbachev give the other's nation a new year's address. February 22–25, 1986 – People Power Revolution successfully overthrows Ferdinand Marcos in the Philippines. April 26, 1986 – The Chernobyl Disaster. October 11–12 – The Reykjavik summit.
The açaí palm ( ə-SY-ee, Brazilian Portuguese: [asaˈi] ; from Nheengatu asai), Euterpe oleracea, is a species of palm tree (Arecaceae) cultivated for its fruit (açaí berries, or simply açaí), hearts of palm (a vegetable), leaves, and trunk wood. Global demand for the fruit has expanded rapidly in the 21st century, and the tree is cultivated for that purpose primarily. The species is native to eastern Amazonia, especially in Brazil, mainly in swamps and floodplains. Açaí palms are tall, slender trees growing to more than 25 m (82 ft) tall, with pinnate leaves up to 3 m (9.8 ft) long. The fruit is small, round, and black-purple in color. The fruit became a staple food in floodplain areas around the 18th century, but its consumption in urban areas and promotion as a health food only began in the mid-1990s along with the popularization of other Amazonian fruits outside the region.
== June 30, 1915 (Wednesday) == Shabin-Karahisar uprising — Out of ammunition, the remaining men of the Armenian militia in the Giresun Province of Turkey engaged Ottoman troops in hand-to-hand combat. Ottoman soldiers defeated the militia and entered the fort the resistance had holed up in to massacre Armenian women, children and elderly inside. British destroyer HMS Lightning struck a mine in the Thames Estuary of England. She broke in two, the bow section sinking with the loss of fifteen of her crew. The stern section was towed to Sheerness, Kent where it was later scrapped. French commander Henri Gouraud was wounded at Gallipoli and replaced by his divisional commander, Maurice Bailloud. German submarine SM UC-2 struck a mine and sank in the North Sea. The Hay Gaol prison closed in Hay, New South Wales, Australia due to its small inmate population (it had only three prisoners). Born: Harry Weese, American architect, designer of the Washington Metro; in Evanston, Illinois, United States (d. 1998) Died: Preston Watson, 35, Scottish aviator, designer of aircraft that could be airborne under their own power; killed in a plane crash (b. 1880)
Sources: en.wikipedia.org
The term flourishing, in positive psychology, refers to optimal human functioning. It comprises four parts: goodness, generativity, growth, and resilience (Fredrickson, 2005). According to Fredrickson (2005), goodness is made up of: happiness, contentment, and effective performance; generativity is about making life better for future generations, and is defined by "broadened thought-action repertoires and behavioral flexibility"; growth involves the use of personal and social assets; and resilience reflects survival and growth after enduring a hardship. A flourishing life stems from mastering all four of these parts. Two contrasting ideologies are languishing and psychopathology. On the mental health continuum, these are considered intermediate mental health disorders, reflecting someone living an unfulfilled and perhaps meaningless life. Those who languish experience more emotional pain, psychosocial deficiency, restrictions in regular activities, and missed workdays. Fredrickson & Losada (2005) conducted a study on university students, operationalizing positive and negative affect. Based on a mathematical model which has been strongly criticized, and now been formally withdrawn by Fredrickson as invalid, Fredrickson & Losada claimed to have discovered a critical positivity ratio, above which people would flourish and below which they would not.
== Applications == Cyanuric acid is used as a chlorine stabilizer / buffer in swimming pools. It binds to free chlorine and releases it slowly, extending the time needed to deplete each dose of sanitizer. A chemical equilibrium exists between the acid with free chlorine and its chlorinated form.
=== Read trimming === Sometimes, the raw reads produced by the sequencer are correct and precise only in a fraction of their length. Using the entire read may introduce artifacts in the downstream analyses like genome assembly, SNP calling, or gene expression estimation. Two classes of trimming programs have been introduced, based on the window-based or the running-sum classes of algorithms. This is a partial list of the trimming algorithms currently available, specifying the algorithm class they belong to:
While the fair was profitable, it nevertheless left Knoxville in debt, and failed to spark the redevelopment boom Testerman, Tyree, and the fair's promoters had envisioned. Furthermore, on the day after the fair closed, the FDIC raided all of Butcher's banks, leading to the collapse of his banking empire, and threatening the city's financial stability. Testerman replaced an embattled Tyree as mayor in 1983, and attempted to reinvigorate interest in his downtown redevelopment plans.
I have frequently seen neglected wounds ... filled with maggots ... as far as my experience extends, these worms eat only dead tissues, and do not injure specifically the well parts. The first documented therapeutic use of maggots in the United States is credited to a second Confederate medical officer Dr. J.F. Zacharias, who reported during the American Civil War that:
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.